Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery

Table 1

Comparisons of clinicopathological characteristics among 192 HCC patients with different HLA-DR+ T cell ratio groups.

Variables		Total (N)	High HLADR+ T cell ratio (N)	Low HLADR+ T cell ratio (N)	χ^2	value
Age	<60 years	115	55	60	2.082	0.149
	≥60 years	77	45	32
Gender	Male	153	79	74	0.061	0.805
	Female	39	21	18
HbsAg	Positive	164	84	80	0.336	0.562
	Negative	28	16	12
Liver cirrhosis	Yes	114	61	53	0.228	0.633
	No	78	39	39
AFP level	<20 ng/ml	96	52	44	0.334	0.563
	≥20 ng/ml	96	48	48
AST/ALT	<1	123	67	56	0.782	0.376
	≥1	69	33	36
GGT level	<45 U/L	129	70	59	0.749	0.387
	≥45 U/L	63	30	33
Child-Pugh grade	A	187	97	90		1
	B	5	3	2
T cell ratio	<77%	150	70	80	8.062	0.005
	≥77%	42	30	12
CD4+T cell ratio	<41.6%	124	66	58|	0.669
	≥41.6%	68	34	34
CD8+ T cell ratio	<29.6%	126	54	72	12.052	<0.001
	≥29.6%	66	46	20
B cell ratio	<18.2%	154	88	66	7.981	0.005
	≥18.2%	38	12	26
NK cell ratio	<25.6%	168	90	78	1.193	0.275
	≥25.6%	24	10	14
Largest tumor size	<5 cm	142	71	71	0.948	0.330
	≥5 cm	50	29	21
Edmondson grade	I-II	116	56	60	1.702	0.192
	III-IV	76	44	32		|
Microvascular invasion	Yes	67	32	35	0.770	0.380
	No	125	68	57
Capsular invasion	Yes	70	38	32	0.214	0.644
	No	122	62	60
Prophylactic TACE after surgery	Yes	65	31	34	0.759	0.384
	No	127	69	58

AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; TACE: transcatheter arterial chemoembolization.